A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).
November 12, 2008
Cutting-edge treatments for hepatocellular carcinoma, including contrast-enhanced ultrasound, combined CRT/TACE, sorafenib, & LCCRT for patients with PVT.
Key findings from the 2008 ASCO Breast Cancer conference; updates on goserelin, capecitabine, docetaxel & lapatinib.
Reporting on new research and emerging trends in breast and liver cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5